博纳吐单抗对比化疗用于儿童及青少年B-ALL首次复发的随机临床试验
IMPORTANCE: Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults is associated with high rates of severe toxicities, subsequent relapse, and death, especially for patients with early relapse (high risk) …
要点
- 博纳吐单抗组2年无病生存率54.4% vs 化疗组39.0%,差异未达预设显著性阈值。
- 博纳吐单抗组2年总生存率71.3% vs 化疗组58.4%,HR 0.62(95%CI 0.39-0.98)。
- 博纳吐单抗组感染、发热性中性粒细胞减少等严重不良事件发生率显著低于化疗组。
核心结论
- 在高危和中危B-ALL首次复发的儿童、青少年和年轻成人中,再诱导后使用博纳吐单抗对比化疗后桥接移植,未使无病生存期达到统计学显著差异。
- 研究因提前终止可能对主要终点把握度不足,解释受限。
研究设计与样本
- 纳入1-30岁B-ALL首次复发患者,排除唐氏综合征、费城染色体阳性ALL、既往造血干细胞移植或既往博纳吐单抗治疗者,共669例。
- 所有患者接受4周再诱导化疗后随机分配接受2周期博纳吐单抗(n=105)或2周期多药化疗(n=103),随后均进行移植。
主要发现
- 208例随机患者中位年龄9岁,女性97例(47%),118例(57%)完成随机治疗。
- 博纳吐单抗组严重不良事件:感染15%、发热性中性粒细胞减少5%、脓毒症2%、黏膜炎1%;化疗组分别为感染65%、发热性中性粒细胞减少58%、脓毒症27%、黏膜炎28%。
关键数值与推荐
- 随机化因数据与安全监察委员会建议而终止,未达到疗效或无效停止规则,此时计划131例事件中发生80例。
临床怎么用
- 对于高危和中危B-ALL首次复发的儿童及年轻成人,再诱导后采用博纳吐单抗巩固较化疗可能改善总生存且严重不良事件更少,但无病生存获益未达统计学显著。
- 临床决策需结合提前终止导致的把握度不足问题,个体化评估后考虑博纳吐单抗作为移植前巩固选项。
局限性
- 研究提前终止,主要终点可能把握度不足。
- 仅57%随机患者完成随机治疗,可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults is associated with high rates of severe toxicities, subsequent relapse, and death, especially for patients with early relapse (high risk) or late relapse with residual disease after reinduction chemotherapy (intermediate risk). Blinatumomab, a bispecific CD3 to CD19 T cell-engaging antibody construct, is efficacious in relapsed/refractory B-ALL and has a favorable toxicity profile. OBJECTIVE: To determine whether substituting blinatumomab for intensive chemotherapy in consolidation therapy would improve survival in children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL. DESIGN, SETTING, AND PARTICIPANTS: This trial was a randomized phase 3 clinical trial conducted by the Children's Oncology Group at 155 hospitals in the US, Canada, Australia, and New Zealand with enrollment from December 2014 to September 2019 and follow-up until September 30, 2020. Eligible patients included those aged 1 to 30 years with B-ALL first relapse, excluding those with Down syndrome, Philadelphia chromosome-positive ALL, prior hematopoietic stem cell transplant, or prior blinatumomab treatment (n = 669). INTERVENTIONS: All patients received a 4-week reinduction chemotherapy course, followed by randomized assignment to receive 2 cycles of blinatumomab (n = 105) or 2 cycles of multiagent chemotherapy (n = 103), each followed by transplant. MAIN OUTCOME AND MEASURES: The primary end point was disease-free survival and the secondary end point was overall survival, both from the time of randomization. The threshold for statistical significance was set at a 1-sided P <.025. RESULTS: Among 208 randomized patients (median age, 9 years; 97 [47%] females), 118 (57%) completed the randomized therapy. Randomization was terminated at the recommendation of the data and safety monitoring committee without meeting stopping rules for efficacy or futility; at that point, 80 of 131 planned events occurred. With 2.9 years of median follow-up, 2-year disease-free survival was 54.4% for the blinatumomab group vs 39.0% for the chemotherapy group (hazard ratio for disease progression or mortality, 0.70 [95% CI, 0.47-1.03]); 1-sided P = .03). Two-year overall survival was 71.3% for the blinatumomab group vs 58.4% for the chemotherapy group (hazard ratio for mortality, 0.62 [95% CI, 0.39-0.98]; 1-sided P = .02). Rates of notable serious adverse events included infection (15%), febrile neutropenia (5%), sepsis (2%), and mucositis (1%) for the blinatumomab group and infection (65%), febrile neutropenia (58%), sepsis (27%), and mucositis (28%) for the chemotherapy group. CONCLUSIONS AND RELEVANCE: Among children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL, postreinduction treatment with blinatumomab compared with chemotherapy, followed by transplant, did not result in a statistically significant difference in disease-free survival. However, study interpretation is limited by early termination with possible underpowering for the primary end point. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02101853.
引用
- Brown PA, Ji L, Xu X, et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021. PMID: 33651090. doi:10.1001/jama.2021.0669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。